335 related articles for article (PubMed ID: 26199353)
1. Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail.
Van Schependom J; Gielen J; Laton J; Nagels G
Mult Scler; 2016 Mar; 22(3):389-92. PubMed ID: 26199353
[TBL] [Abstract][Full Text] [Related]
2. Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
Faulkner M
Expert Opin Drug Saf; 2015; 14(11):1737-48. PubMed ID: 26394704
[TBL] [Abstract][Full Text] [Related]
3. Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.
De Mercanti SF; Gned D; Matta M; Iudicello M; Franchin E; Clerico M
J Investig Med High Impact Case Rep; 2020; 8():2324709620939802. PubMed ID: 32646245
[TBL] [Abstract][Full Text] [Related]
4. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
Warnke C; Olsson T; Hartung HP
Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
[TBL] [Abstract][Full Text] [Related]
5. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
Oshima Y; Tanimoto T; Yuji K; Tojo A
Mult Scler; 2019 Jul; 25(8):1141-1149. PubMed ID: 29985084
[TBL] [Abstract][Full Text] [Related]
6. Three cases of non-carryover fingolimod-PML: Is the risk in Japan increased?
Nakahara J; Tomaske L; Kume K; Takata T; Kamada M; Deguchi K; Kufukihara K; Schneider R; Gold R; Ayzenberg I
Neurol Neuroimmunol Neuroinflamm; 2019 May; 6(3):e559. PubMed ID: 31044147
[TBL] [Abstract][Full Text] [Related]
7. Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.
Jordan AL; Yang J; Fisher CJ; Racke MK; Mao-Draayer Y
Mult Scler; 2022 Jan; 28(1):7-15. PubMed ID: 32808554
[TBL] [Abstract][Full Text] [Related]
8. Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.
D'Amico E; Zanghì A; Leone C; Tumani H; Patti F
Drug Saf; 2016 Dec; 39(12):1163-1174. PubMed ID: 27696299
[TBL] [Abstract][Full Text] [Related]
9. [Progressive Multifocal Leukoencephalopathy: An Overview of Current Topics].
Yukitake M
Brain Nerve; 2022 Oct; 74(10):1179-1187. PubMed ID: 36198643
[TBL] [Abstract][Full Text] [Related]
10. Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data.
Sinnecker T; Hadisurya J; Schneider-Hohendorf T; Schwab N; Wrede K; Gembruch O; Gold R; Hellwig K; Pilgram-Pastor S; Adams O; Albrecht P; Hartung HP; Aktas O; Kraemer M
BMC Neurol; 2019 Aug; 19(1):190. PubMed ID: 31399069
[TBL] [Abstract][Full Text] [Related]
11. PML in a patient with lymphocytopenia treated with dimethyl fumarate.
Rosenkranz T; Novas M; Terborg C
N Engl J Med; 2015 Apr; 372(15):1476-8. PubMed ID: 25853765
[No Abstract] [Full Text] [Related]
12. PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
Lehmann-Horn K; Penkert H; Grein P; Leppmeier U; Teuber-Hanselmann S; Hemmer B; Berthele A
Neurology; 2016 Jul; 87(4):440-1. PubMed ID: 27343070
[No Abstract] [Full Text] [Related]
13. A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence.
Diebold M; Altersberger V; Décard BF; Kappos L; Derfuss T; Lorscheider J
Mult Scler; 2019 Oct; 25(12):1682-1685. PubMed ID: 31208265
[TBL] [Abstract][Full Text] [Related]
14. Fingolimod-associated PML in a patient with prior immunosuppression.
Gyang TV; Hamel J; Goodman AD; Gross RA; Samkoff L
Neurology; 2016 May; 86(19):1843-5. PubMed ID: 27164718
[No Abstract] [Full Text] [Related]
15. Effect of dosage reduction on peripheral blood lymphocyte count in patients with multiple sclerosis receiving long-term fingolimod therapy.
Takahashi K
J Clin Neurosci; 2019 May; 63():91-94. PubMed ID: 30772201
[TBL] [Abstract][Full Text] [Related]
16. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
Pistono C; Osera C; Boiocchi C; Mallucci G; Cuccia M; Bergamaschi R; Pascale A
Pharmacol Res; 2017 Jun; 120():279-293. PubMed ID: 28396093
[TBL] [Abstract][Full Text] [Related]
17. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
[TBL] [Abstract][Full Text] [Related]
18. Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature.
Sriwastava S; Chaudhary D; Srivastava S; Beard K; Bai X; Wen S; Khalid SH; Lisak RP
J Neurol; 2022 Mar; 269(3):1678-1687. PubMed ID: 34800168
[TBL] [Abstract][Full Text] [Related]
19. PML in DMF-treated patients with normal lymphocytes: Worried well or well to be worried?
Carruthers RL; Healy BC
Mult Scler; 2016 Mar; 22(3):394-5. PubMed ID: 26163066
[No Abstract] [Full Text] [Related]
20. Progressive multifocal leukoencephalopathy in a patient taking the MS pill Gilenya.
Clin Infect Dis; 2013 Oct; 57(8):ii. PubMed ID: 24195115
[No Abstract] [Full Text] [Related]
[Next] [New Search]
